Mitoconix Bio Raises $20 Million in Series A Funding to Develop Neurodegenerative Disease Therapies
Proceeds will be used to advance the Company's lead product through preclinical and clinical development and expand its therapeutic pipeline for treating neurodegenerative disorders by improving mitochondrial function
NESS ZIONA, Israel, June 27, 2017 -... Biopharmaceuticals, Neurology, Venture Capital Mitoconix Bio, Huntington's disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Brain | Funding | Huntington's Disease | Middle East Health | Mitochondrial Disease | Neurology | Pharmaceuticals | Venture Capital